FFA
RIGL icon

Frazier Financial Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Frazier Financial Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$487 Buy
+18
New +$605 ﹤0.01% 710

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Frazier Financial Advisors's RIGL Position: Q1 2026 in Review

Frazier Financial Advisors opened a new position in Rigel Pharmaceuticals (RIGL) in Q1 2026: 18 shares worth $487. The stake represents ﹤0.01% of the portfolio and ranks #710 among its holdings.

159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Frazier Financial Advisors held 18 shares of Rigel Pharmaceuticals worth $487 as of Q1 2026.
  • Rigel Pharmaceuticals was a new Frazier Financial Advisors position in Q1 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Frazier Financial Advisors's portfolio in Q1 2026, its #710 holding.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Frazier Financial Advisors's 13F filing for Q1 2026, filed 5 May 2026.